RAGHU KALLURI to Proto-Oncogene Proteins p21(ras)
This is a "connection" page, showing publications RAGHU KALLURI has written about Proto-Oncogene Proteins p21(ras).
Connection Strength
2.569
-
KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T?cells. Cancer Cell. 2023 09 11; 41(9):1606-1620.e8.
Score: 0.575
-
Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T?cells. Dev Cell. 2023 09 11; 58(17):1562-1577.e8.
Score: 0.575
-
Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic KrasG12D in pancreatic cancer. Life Sci Alliance. 2021 09; 4(9).
Score: 0.497
-
Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight. 2018 04 19; 3(8).
Score: 0.397
-
Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer. Cancer Discov. 2020 07; 10(7):1058-1077.
Score: 0.114
-
Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells. Cancer Immunol Res. 2017 09; 5(9):718-729.
Score: 0.094
-
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017 06 22; 546(7659):498-503.
Score: 0.093
-
Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer. Cancer Biol Ther. 2017 03 04; 18(3):158-165.
Score: 0.091
-
Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem. 2014 Feb 14; 289(7):3869-75.
Score: 0.074
-
Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat Med. 2016 05; 22(5):497-505.
Score: 0.022
-
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015 Jul 09; 523(7559):177-82.
Score: 0.020
-
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell. 2011 Sep 13; 20(3):400-13.
Score: 0.016